Recce Pharma Clears Indonesian Inspection for Phase 3 Diabetic Foot Trial
Recce Pharmaceuticals Phase 3 inspection clears key regulatory hurdle in Indonesia
Recce Pharmaceuticals (ASX: RCE) has received positive results from a comprehensive regulatory inspection of its Phase 3 clinical trial site in Indonesia. The Indonesian National Agency of Drug and Food Control (Badan POM) completed the routine inspection with no findings that prevent the ongoing study from continuing, clearing a critical regulatory hurdle for the company’s lead diabetic foot infection programme.
The inspection reviewed the R327-G301 trial, which is evaluating RECCE® 327 (R327) for the treatment of diabetic foot infections. Patient dosing continues across five clinical trial sites, with interim data analysis expected once 155 patients have completed the study. Regulatory approval in Indonesia is anticipated in CY26.
The clean inspection outcome validates the quality of data collection and trial conduct, removing a material execution risk from the company’s registrational pathway. For investors, this represents a significant de-risking milestone that supports the timeline toward commercialisation in Indonesia and broader ASEAN markets.
When big ASX news breaks, our subscribers know first
What a GCP inspection means for clinical trial investors
A Good Clinical Practice (GCP) regulatory inspection examines how a clinical trial is being conducted at participating sites. Regulators review trial processes, data integrity, patient safety protocols, and compliance with international standards that govern clinical research.
When an inspection finds no issues requiring corrective action, it confirms that the data being collected meets the quality standards necessary for eventual regulatory submission. This validation is critical because flawed trial conduct can lead to rejected data, requiring companies to repeat studies or conduct additional trials.
In Recce’s case, Badan POM has not requested any changes to the ongoing R327-G301 trial. This outcome provides confidence that the Phase 3 data will be acceptable to Indonesian regulators when the company submits its application for marketing approval, reducing the risk of delays or additional requirements during the approval process.
Indonesia’s diabetic foot infection market opportunity
Indonesia presents a substantial commercial opportunity for diabetic foot infection therapies. The country faces a significant diabetes burden that positions it as a strategically important first market for Recce’s R327 programme.
Key market statistics:
- 20.9 million adults living with diabetes in Indonesia
- 11% of the Indonesian population affected by diabetes
- Fifth highest diabetes prevalence globally
- US$1.5 billion Asia-Pacific diabetic foot ulcer market opportunity
Indonesia serves as a gateway to broader ASEAN and Asia-Pacific commercialisation. The prevalence of diabetes-related complications in the region creates a defined expansion pathway following initial regulatory approval. The company’s strategy positions R327 to enter a large, underserved market with significant unmet medical need.
CEO commentary on trial progress
James Graham, Chief Executive Officer
“We are pleased with the outcome of BPOM’s inspection, which reinforces the high standards of our clinical program maintained by our teams and partners working throughout Indonesia. This result provides further confidence in the integrity of our data collection and the robustness of our development pathway as we progress towards potential regulatory approval.”
Graham emphasised the company’s ongoing engagement with Badan POM as the Phase 3 trial advances toward its interim analysis milestone. The inspection outcome validates the quality systems established by Recce and its Indonesian clinical partners.
Recce’s broader anti-infective pipeline
The Phase 3 inspection relates specifically to R327, the company’s lead intravenous and topical therapy. However, Recce has developed a broader pipeline of synthetic polymer anti-infectives targeting bacterial and viral infections.
Recce’s three patented compounds:
- RECCE® 327 (R327) – Intravenous and topical therapy for serious bacterial infections, including superbug strains
- RECCE® 435 (R435) – Oral therapy for bacterial infections
- RECCE® 529 (R529) – Anti-viral compound
R327 has received Qualified Infectious Disease Product (QIDP) designation from the FDA under the Generating Antibiotic Initiatives Now (GAIN) Act. This designation provides Fast Track status and 10 years of market exclusivity post-approval in the United States, representing significant commercial protection beyond standard patent life.
The World Health Organization has recognised all three compounds on its list of antibacterial products in clinical development for priority pathogens. Recce wholly owns its automated manufacturing capability, supporting current clinical trials and providing supply chain control as the company advances toward commercialisation.
The next major ASX story will hit our subscribers first
Key milestones and timelines ahead
Recce has outlined near-term catalysts that will define the commercial pathway for R327 in Southeast Asia. The interim data analysis at 155 patients completed represents the next major trial milestone, providing an initial assessment of efficacy and safety in the Indonesian patient population.
| Milestone | Expected Timing |
|---|---|
| Interim data analysis | At 155 patients completed |
| Indonesian regulatory approval | CY26 |
| ASEAN expansion | Post-Indonesia approval |
The CY26 approval timeline positions R327 as a near-term commercialisation opportunity within the company’s pipeline. Following Indonesian approval, the company plans to pursue registrations in other ASEAN countries, leveraging the initial regulatory success to expand market access across the region. This staged approach provides a defined pathway to capture the broader Asia-Pacific diabetic foot ulcer market.
Ready to Learn More About Recce Pharmaceuticals’ Anti-Infective Pipeline?
The Phase 3 inspection outcome validates RECCE® 327’s development pathway in Indonesia, with regulatory approval targeted for CY26. This milestone reduces execution risk whilst confirming the company’s position in a US$1.5 billion Asia-Pacific market opportunity.
To explore Recce’s full pipeline of patented anti-infective compounds and upcoming trial milestones, visit the Recce Pharmaceuticals investor centre. Stay informed on developments as the company progresses toward commercialisation across ASEAN markets.